Syndax’s Q1 Upswing: A Revenue-First Quarter That Could Redefine the Roadmap for Niche Oncology

Syndax Pharmaceuticals, Inc. (SNDX) reports Q1 2026 results; EPS and EPS consensus are not highlighted in the release, and there’s no explicit revenue forecast provided. Still, the numbers pulse with a story about momentum in targeted therapies and collaboration-driven growth.

Lede: a revenue narrative with a clear tilt toward growth, not a single number

The first quarter of 2026 brought total revenue of $64.9 million for Syndax, a 224% year-over-year leap. The surge is powered by Revuforj, the company’s menin inhibition program, which logged $49 million in net revenue for 1Q26, and Niktimvo (axatilimab-csfr), which contributed $55.1 million in net revenue. Put differently, the two lead programs together pushed net sales past the $100 million mark in the quarter. In addition, Syndax recognized $15.9 million in collaboration revenue tied to its partnerships.

Noticeably, the press release centers on top-line revenue and program uptake rather than earnings per share (EPS). There is no stated full-year revenue forecast in the release, and there is no explicit EPS consensus or earnings surprise disclosed within these materials. In other words, investors get a strong revenue narrative, but not a ready-made EPS surprise or an EPS consensus target from management in this document.

What the numbers say, with a closer look at the pacing

The quarterly performance signals a disciplined go-to-market for two differentiated oncology assets. Revuforj’s $49 million in net revenue underscores sustained payer access and adoption in both R/R NPM1m AML and broader menin-inhibition indications. Niktimvo—axatilimab-csfr—delivered $55.1 million, reinforcing Syndax’s ability to monetize an aligned portfolio alongside Revuforj. The combined net sales across these products suggest that the company is building a diversified, pipeline-backed revenue engine rather than leaning on a single asset for growth.

The company frames topline momentum as the core narrative, with upcoming data readouts that could alter the trajectory. New Revumenib real-world data and frontline results are expected in 2Q26, while topline Phase 2 data for axatilimab in IPF and chronic GVHD are anticipated in 4Q26. Those milestones matter because they could translate into value creation even if GAAP EPS moves only incrementally in the near term.

CEO Michael A. Metzger underscored the leverage of the business model: enhanced revenue flow from lead programs, plus meaningful collaboration revenue, positions Syndax to progress toward profitability while continuing to invest in data generation and clinical milestones.

Implications for Syndax and its sector peers

From a strategic lens, this quarter reinforces the appeal of a dual-path revenue model that blends direct product sales with collaboration upside. For biopharma peers pursuing niche oncology franchises, the takeaway is plain: robust top-line growth supported by partner-driven monetization can sustain a long runway of research and development without over-reliance on one product’s commercial cycle.

However, the absence of a dedicated EPS figure or explicit full-year revenue forecast means the market will likely crave more guidance on profitability and cost structure before re-rating on the back of this quarter alone. In practice, investors will watch for the EPS trajectory and any new revenue outlook to gauge whether the current momentum can translate into an earnings surprise in future quarters, or whether the stock’s multiple hinges on milestone-driven data rather than quarterly margin expansion.

In terms of the broader sector, Syndax’s results spotlight the potential for early-stage, data-rich programs to drive evaluation upside even as the industry remains vulnerable to data timing, regulatory nuances, and competitive dynamics in targeted therapies. If the upcoming topline results validate the current narrative, peers with parallel assets in similar stages could benefit from cross-cutting enthusiasm around precision oncology and mechanism-specific inhibitors.

Next steps and what to watch

The quarterly call, scheduled for 4:30 p.m. ET, will be the focal point for fresh guidance on revenue trajectory, gross margins, and operating expenses. Market participants will be listening for any updates to the revenue forecast, clarifications on the EPS path, and color on how the cost structure may evolve as production scales with higher net revenues. Milestone-driven data readouts—especially the 2Q26 Revumenib real-world data and 4Q26 axatilimab topline results—will serve as critical inflection points for both Syndax and its peers.

In the near term, a positive reception to the milestones could push the narrative toward a favorable reevaluation of the stock, particularly if the company demonstrates discipline in cost management and a clear path to sustainable profitability. In the longer run, the question remains whether the portfolio can sustain growth beyond the mid-cycle data events and how the collaboration framework continues to translate into meaningful, recurring revenue streams as the pipeline matures.